J&J Unlikely To Cut Risperdal Deals As Appeals Play Out

By Matt Fair (November 29, 2016, 7:34 PM EST) -- Even after four losses — including a recent $70 million verdict — and another trial opening this week, attorneys say Johnson & Johnson is unlikely to consider settling thousands of pending cases over breast growth allegedly caused by the antipsychotic Risperdal until appeals over the availability of punitive damages and the appropriate time bar for claims are resolved....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!